Fig. 2.
Continuous haloperidol (0.5mg/kg/day via minipump; CONT-HAL), but not continuous olanzapine (10mg/kg/day via minipump; CONT-OLZ) or intermittent olanzapine (1mg/kg/day via subcutaneous [SC] injection; INT-OLZ) treatment enhanced the ability of amphetamine (AMPH) to potentiate operant responding for a conditioned reward. n′s = 14/condition. *P < .05 compared with vehicle (VEH) and INT-OLZ. Data are means ± SEM. VEH, group injected daily with SC phosphate-buffered saline. SAL, saline.
